Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Gastric Cancer

Free Subscription Articles published in BMC Cancer Retrieve available abstracts of 249 articles: HTML format

Single Articles

May 2024
1. PANG H, Dai L, Chen L, Chen X, et al
   Prognostic value of the advanced lung cancer inflammation index in patients with gastric cancer after radical gastrectomy: a propensity-score matching cohort study and meta-analysis.
   BMC Cancer. 2024;24:583.
   PubMed     Abstract available
   
   
   
2. CHE B, Yuan S, Zhang H, Zhai J, et al
   Causal inference between pernicious anemia and cancers: a bidirectional two-sample mendelian randomization analysis.
   BMC Cancer. 2024;24:586.
   PubMed     Abstract available
   
   
   
3. WANG S, Zhang W, Wu X, Zhu Z, et al
   Comprehensive analysis of T-cell regulatory factors and tumor immune microenvironment in stomach adenocarcinoma.
   BMC Cancer. 2024;24:570.
   PubMed     Abstract available
   
   
   April 2024
4. ZHAN Z, Chen B, Cheng H, Xu S, et al
   Identification of prognostic signatures in remnant gastric cancer through an interpretable risk model based on machine learning: a multicenter cohort study.
   BMC Cancer. 2024;24:547.
   PubMed     Abstract available
   
   
   
5. CHOI Y, Lee J, Shin K, Lee JW, et al
   Integrated clinical and genomic models using machine-learning methods to predict the efficacy of paclitaxel-based chemotherapy in patients with advanced gastric cancer.
   BMC Cancer. 2024;24:502.
   PubMed     Abstract available
   
   
   
6. TAN Y, Feng LJ, Huang YH, Xue JW, et al
   Correction: Development and validation of a Radiopathomics model based on CT scans and whole slide images for discriminating between Stage I-II and Stage III gastric cancer.
   BMC Cancer. 2024;24:469.
   PubMed    
   
   
   
7. LIU SS, Wan QS, Lv C, Wang JK, et al
   Integrating trans-omics, cellular experiments and clinical validation to identify ILF2 as a diagnostic serum biomarker and therapeutic target in gastric cancer.
   BMC Cancer. 2024;24:465.
   PubMed     Abstract available
   
   
   
8. LUNA J, Picker N, Wilke T, Lutz M, et al
   Real-world evidence of treatment patterns and survival of metastatic gastric cancer patients in Germany.
   BMC Cancer. 2024;24:462.
   PubMed     Abstract available
   
   
   
9. LI F, Dou J, Wei L, Li S, et al
   Biomarkers of lipid metabolism in gastric cancer: a case control study.
   BMC Cancer. 2024;24:455.
   PubMed     Abstract available
   
   
   
10. ZHONG Y, Xiao YY, Ye JY, Jian GL, et al
    Diagnostic efficacy of contrast-enhanced gastric ultrasonography in staging gastric cancer: a meta-analysis.
    BMC Cancer. 2024;24:422.
    PubMed     Abstract available
    
    
    
11. ZHAN PC, Yang S, Liu X, Zhang YY, et al
    A radiomics signature derived from CT imaging to predict MSI status and immunotherapy outcomes in gastric cancer: a multi-cohort study.
    BMC Cancer. 2024;24:404.
    PubMed     Abstract available
    
    
    March 2024
12. YOON C, Lu J, Jun Y, Suh YS, et al
    Retraction Note: KRAS activation in gastric cancer stem-like cells promotes tumor angiogenesis and metastasis.
    BMC Cancer. 2024;24:392.
    PubMed    
    
    
    
13. TAN Y, Feng LJ, Huang YH, Xue JW, et al
    Development and validation of a Radiopathomics model based on CT scans and whole slide images for discriminating between Stage I-II and Stage III gastric cancer.
    BMC Cancer. 2024;24:368.
    PubMed     Abstract available
    
    
    
14. LIU D, Quan H, Ma M, Zhou H, et al
    Nomogram to predict overall survival of patients receiving radical gastrectomy and incomplete peri-operative adjuvant chemotherapy for stage II/III gastric cancer: a retrospective bi-center cohort study.
    BMC Cancer. 2024;24:344.
    PubMed     Abstract available
    
    
    
15. CHEN Y, Chen X, Lin Y, Zhang S, et al
    Correction: Oncological risk of proximal gastrectomy for proximal advanced gastric cancer after neoadjuvant chemotherapy.
    BMC Cancer. 2024;24:314.
    PubMed    
    
    
    
16. WANG J, Shao M, Hu H, Xiao W, et al
    Convolutional neural network applied to preoperative venous-phase CT images predicts risk category in patients with gastric gastrointestinal stromal tumors.
    BMC Cancer. 2024;24:280.
    PubMed     Abstract available
    
    
    February 2024
17. ZHANG J, Wang L, Zhang S, Cao R, et al
    Alpha-fetoprotein predicts the treatment efficacy of immune checkpoint inhibitors for gastric cancer patients.
    BMC Cancer. 2024;24:266.
    PubMed     Abstract available
    
    
    
18. CHEN Y, Chen X, Lin Y, Zhang S, et al
    Oncological risk of proximal gastrectomy for proximal advanced gastric cancer after neoadjuvant chemotherapy.
    BMC Cancer. 2024;24:255.
    PubMed     Abstract available
    
    
    
19. LIM SH, Lee KW, Kim JJ, Im HS, et al
    Real-world outcomes of third-line immune checkpoint inhibitors versus irinotecan-based chemotherapy in patients with advanced gastric cancer: a Korean, multicenter study (KCSG ST22-06).
    BMC Cancer. 2024;24:252.
    PubMed     Abstract available
    
    
    
20. LI ZZ, Yan XL, Zhang Z, Chen JL, et al
    Prognostic value of GLIM-defined malnutrition in combination with hand-grip strength or gait speed for the prediction of postoperative outcomes in gastric cancer patients with cachexia.
    BMC Cancer. 2024;24:253.
    PubMed     Abstract available
    
    
    
21. DE MORAES FCA, Pasqualotto E, Chavez MP, Ferreira ROM, et al
    Efficacy and safety of Zolbetuximab plus chemotherapy for advanced CLDN18.2-positive gastric or gastro-oesophageal adenocarcinoma: a meta-analysis of randomized clinical trials.
    BMC Cancer. 2024;24:240.
    PubMed     Abstract available
    
    
    
22. SUI H, Lou A, Li Z, Yang J, et al
    Retraction Note: Lidocaine inhibits growth, migration and invasion of gastric carcinoma cells by up-regulation of miR-145.
    BMC Cancer. 2024;24:241.
    PubMed    
    
    
    
23. ZHENG HL, Wang FH, Zhang LK, Li P, et al
    Trajectories of neutrophil-to-lymphocyte ratios during neoadjuvant chemotherapy correlate with short- and long-term outcomes in gastric cancer: a group-based trajectory analysis.
    BMC Cancer. 2024;24:226.
    PubMed     Abstract available
    
    
    
24. FARAMARZI S, Kiani B, Faramarzi S, Firouraghi N, et al
    Cancer patterns in Iran: a gender-specific spatial modelling of cancer incidence during 2014-2017.
    BMC Cancer. 2024;24:191.
    PubMed     Abstract available
    
    
    January 2024
25. HONG Z, Wen P, Wang K, Wei X, et al
    The macrophage-associated prognostic gene ANXA5 promotes immunotherapy resistance in gastric cancer through angiogenesis.
    BMC Cancer. 2024;24:141.
    PubMed     Abstract available
    
    
    
26. WEI L, Wu X, Wang L, Chen L, et al
    Expression and prognostic value of APOBEC2 in gastric adenocarcinoma and its association with tumor-infiltrating immune cells.
    BMC Cancer. 2024;24:15.
    PubMed     Abstract available
    
    
    
27. QU T, Zhang S, Yang S, Li S, et al
    Utilizing serum metabolomics for assessing postoperative efficacy and monitoring recurrence in gastric cancer patients.
    BMC Cancer. 2024;24:27.
    PubMed     Abstract available
    
    
    December 2023
28. ZHU G, Cai H, Xiao Q, Zeng S, et al
    GRB7 plays a promoting role in the progression of gastric cancer.
    BMC Cancer. 2023;23:1262.
    PubMed     Abstract available
    
    
    
29. CHE J, Zhao Y, Gu B, Li S, et al
    Untargeted serum metabolomics reveals potential biomarkers and metabolic pathways associated with the progression of gastroesophageal cancer.
    BMC Cancer. 2023;23:1238.
    PubMed     Abstract available
    
    
    
30. NIE C, Xu W, Guo Y, Gao X, et al
    Immune checkpoint inhibitors enhanced the antitumor efficacy of disitamab vedotin for patients with HER2-positive or HER2-low advanced or metastatic gastric cancer: a multicenter real-world study.
    BMC Cancer. 2023;23:1239.
    PubMed     Abstract available
    
    
    
31. GAO J, Lan J, Liao H, Yang F, et al
    Promising preclinical patient-derived organoid (PDO) and xenograft (PDX) models in upper gastrointestinal cancers: progress and challenges.
    BMC Cancer. 2023;23:1205.
    PubMed     Abstract available
    
    
    
32. BOBRZYNSKI L, Sedlak K, Rawicz-Pruszynski K, Kolodziejczyk P, et al
    Evaluation of optimum classification measures used to define textbook outcome among patients undergoing curative-intent resection of gastric cancer.
    BMC Cancer. 2023;23:1199.
    PubMed     Abstract available
    
    
    
33. JEON CH, Park KB, Lee H, Kim DJ, et al
    Refining gastric cancer staging: examining the interplay between number and anatomical location of metastatic lymph nodes - a retrospective multi-institutional study.
    BMC Cancer. 2023;23:1192.
    PubMed     Abstract available
    
    
    November 2023
34. WEI C, He Y, Luo M, Chen G, et al
    The role of computed tomography features in assessing response to neoadjuvant chemotherapy in locally advanced gastric cancer.
    BMC Cancer. 2023;23:1157.
    PubMed     Abstract available
    
    
    
35. ZHENG H, Yin X, Pan T, Tao X, et al
    Effect of different surgical approaches on the survival and safety of Siewert type II esophagogastric junction adenocarcinoma: a systematic review and meta-analysis.
    BMC Cancer. 2023;23:1130.
    PubMed     Abstract available
    
    
    
36. CHEN YY, Li BP, Wang JF, Wang Y, et al
    Investigating the prognostic and predictive value of the type II cystatin genes in gastric cancer.
    BMC Cancer. 2023;23:1122.
    PubMed     Abstract available
    
    
    
37. LIU X, Ren J, Zhou R, Wen Z, et al
    Construction of iron metabolism-related prognostic features of gastric cancer based on RNA sequencing and TCGA database.
    BMC Cancer. 2023;23:1106.
    PubMed     Abstract available
    
    
    
38. YANG Y, Li Y, Chen Z
    Impact of low serum iron on treatment outcome of PD-1 inhibitors in advanced gastric cancer.
    BMC Cancer. 2023;23:1095.
    PubMed     Abstract available
    
    
    
39. TAKASHIMA Y, Komatsu S, Nishibeppu K, Ohashi T, et al
    A shorter distal resection margin is a surrogate marker of nodal metastasis and poor prognosis in distal gastrectomy for advanced gastric cancer.
    BMC Cancer. 2023;23:1075.
    PubMed     Abstract available
    
    
    October 2023
40. LUKSTA M, Bausys A, Bickaite K, Rackauskas R, et al
    Pressurized intraperitoneal aerosol chemotherapy (PIPAC) with cisplatin and doxorubicin in combination with FOLFOX chemotherapy as a first-line treatment for gastric cancer patients with peritoneal metastases: single-arm phase II study.
    BMC Cancer. 2023;23:1032.
    PubMed     Abstract available
    
    
    
41. QYI YZ, Aung HH, Aye SN, Tung WS, et al
    Toll-like receptor 9 (-1237 T/C, -1486 T/C) and the risk of gastric cancer: a meta-analysis of genetic association studies.
    BMC Cancer. 2023;23:1027.
    PubMed     Abstract available
    
    
    
42. SUN C, Niu P, Zhang X, Zhao L, et al
    Concurrent clinical and pathological response predicts favorable prognosis of patients with gastric cancer after neoadjuvant therapy: a real-world study.
    BMC Cancer. 2023;23:996.
    PubMed     Abstract available
    
    
    
43. MAKUUCHI R, Terashima M, Terada M, Mizusawa J, et al
    Randomized controlled phase III trial to investigate superiority of robot-assisted gastrectomy over laparoscopic gastrectomy for clinical stage T1-4aN0-3 gastric cancer patients (JCOG1907, MONA LISA study): a study protocol.
    BMC Cancer. 2023;23:987.
    PubMed     Abstract available
    
    
    
44. BEIHAGHI M, Sahebi R, Beihaghi MR, Nessiani RK, et al
    Evaluation of rs10811661 polymorphism in CDKN2A / B in colon and gastric cancer.
    BMC Cancer. 2023;23:985.
    PubMed     Abstract available
    
    
    
45. NARA K, Yamamoto T, Yamashita H, Yagi K, et al
    Prior treatment with oxaliplatin-containing regimens and higher total bilirubin levels are risk factors for neutropenia and febrile neutropenia in patients with gastric or esophagogastric junction cancer receiving weekly paclitaxel and ramucirumab the
    BMC Cancer. 2023;23:979.
    PubMed     Abstract available
    
    
    
46. WU D, Lu J, Xue Z, Zhong Q, et al
    Evaluation of dynamic recurrence risk for locally advanced gastric cancer in the clinical setting of adjuvant chemotherapy: a real-world study with IPTW-based conditional recurrence analysis.
    BMC Cancer. 2023;23:964.
    PubMed     Abstract available
    
    
    
47. WANG Y, Guo Z, Tian Y, Cong L, et al
    MAPK1 promotes the metastasis and invasion of gastric cancer as a bidirectional transcription factor.
    BMC Cancer. 2023;23:959.
    PubMed     Abstract available
    
    
    
48. XIANG L, Jin S, Yu Y, Wang D, et al
    Risk of venous thromboembolism in patients undergoing gastric cancer surgery: a systematic review and meta-analysis.
    BMC Cancer. 2023;23:933.
    PubMed     Abstract available
    
    
    
49. WANG Y, Pan J, An F, Chen K, et al
    GBP2 is a prognostic biomarker and associated with immunotherapeutic responses in gastric cancer.
    BMC Cancer. 2023;23:925.
    PubMed     Abstract available
    
    
    
50. XIA B, Gu X, Xu T, Yan M, et al
    Exosomes-mediated transfer of LINC00691 regulates the formation of CAFs and promotes the progression of gastric cancer.
    BMC Cancer. 2023;23:928.
    PubMed     Abstract available
    
    
    September 2023
51. KIM Y, Bae YJ, Kim JH, Kim H, et al
    Wnt/beta-catenin pathway is a key signaling pathway to trastuzumab resistance in gastric cancer cells.
    BMC Cancer. 2023;23:922.
    PubMed     Abstract available
    
    
    
52. SUN Y, Chen C, Hou L, Zhao E, et al
    Short-term and long-term outcomes of patients with gastric cancer during versus before the COVID-19 pandemic: cohort study using propensity score matching method.
    BMC Cancer. 2023;23:913.
    PubMed     Abstract available
    
    
    
53. WU J, Tian S, Xu J, Cheng N, et al
    Association of high-risk comorbidity with overall survival among patients with gastric cancer and its sex-specific differences in China: a retrospective observational cohort study.
    BMC Cancer. 2023;23:916.
    PubMed     Abstract available
    
    
    
54. SAHIN MEH, Akbas F, Yardimci AH, Sahin E, et al
    The effect of sarcopenia and sarcopenic obesity on survival in gastric cancer.
    BMC Cancer. 2023;23:911.
    PubMed     Abstract available
    
    
    
55. MA X, Pierce E, Anand H, Aviles N, et al
    Early prediction of response to palliative chemotherapy in patients with stage-IV gastric and esophageal cancer.
    BMC Cancer. 2023;23:910.
    PubMed     Abstract available
    
    
    
56. ZHAO L, Zhang F, Jiao F, Zhou X, et al
    The minimum number of examined lymph nodes was 24 for optimal survival of pathological T2-4 gastric cancer: a multi-center, hospital-based study covering 20 years of data.
    BMC Cancer. 2023;23:892.
    PubMed     Abstract available
    
    
    August 2023
57. HIGUCHI S, Suehiro Y, Izuhara L, Yoshina S, et al
    BCL7B, a SWI/SNF complex subunit, orchestrates cancer immunity and stemness.
    BMC Cancer. 2023;23:811.
    PubMed     Abstract available
    
    
    
58. DI Y, Ding L, Gao L, Huang H, et al
    Association of meat consumption with the risk of gastrointestinal cancers: a systematic review and meta-analysis.
    BMC Cancer. 2023;23:782.
    PubMed     Abstract available
    
    
    
59. SHIH YH, Lin HC, Liao PW, Chou CW, et al
    The efficacy of adjuvant chemotherapy for older adults with stage II/III gastric cancer: a retrospective cohort study.
    BMC Cancer. 2023;23:770.
    PubMed     Abstract available
    
    
    
60. HAN Y, Wu J, Ji R, Tan H, et al
    Preoperative sarcopenia combined with prognostic nutritional index predicts long-term prognosis of radical gastrectomy with advanced gastric cancer: a comprehensive analysis of two-center study.
    BMC Cancer. 2023;23:751.
    PubMed     Abstract available
    
    
    
61. TAKAHASHI N, Hara H, Nagashima K, Hirata K, et al
    Randomised phase II trial of trifluridine/tipiracil (FTD/TPI) plus ramucirumab (RAM) versus trifluridine/tipiracil for previously treated patients with advanced gastric or esophagogastric junction adenocarcinoma (RETRIEVE study, WJOG15822G).
    BMC Cancer. 2023;23:726.
    PubMed     Abstract available
    
    
    July 2023
62. YOON C, Lu J, Jun Y, Suh YS, et al
    KRAS activation in gastric cancer stem-like cells promotes tumor angiogenesis and metastasis.
    BMC Cancer. 2023;23:690.
    PubMed     Abstract available
    
    
    
63. YANAGIMOTO Y, Imamura H, Adachi S, Odagiri K, et al
    The effect of specimen processing time on HER2 expression in gastric cancer and esophagogastric junction cancer: a single-center retrospective observational study.
    BMC Cancer. 2023;23:645.
    PubMed     Abstract available
    
    
    June 2023
64. HAN Y, Wang X, Xu M, Teng Z, et al
    Aspartoacylase promotes the process of tumour development and is associated with immune infiltrates in gastric cancer.
    BMC Cancer. 2023;23:604.
    PubMed     Abstract available
    
    
    
65. JEON CH, Park KB, Kim S, Seo HS, et al
    Predictive model for long-term weight recovery after gastrectomy for gastric cancer: an introduction to a web calculator.
    BMC Cancer. 2023;23:580.
    PubMed     Abstract available
    
    
    
66. LORENZEN S, Schwarz A, Pauligk C, Goekkurt E, et al
    Ramucirumab plus irinotecan / leucovorin / 5-FU versus ramucirumab plus paclitaxel in patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, who failed one prior line of palliative chemotherapy: the phase II/I
    BMC Cancer. 2023;23:561.
    PubMed     Abstract available
    
    
    
67. SHEN X, Liu H, Zhou H, Cheng Z, et al
    Galectin-1 promotes gastric cancer peritoneal metastasis through peritoneal fibrosis.
    BMC Cancer. 2023;23:559.
    PubMed     Abstract available
    
    
    
68. TIAN Y, Pang Y, Yang PG, Guo HH, et al
    Clinical implications of micro lymph node metastasis for patients with gastric cancer.
    BMC Cancer. 2023;23:536.
    PubMed     Abstract available
    
    
    
69. E Y, Yu Q, Sun T, Xue H, et al
    The relationship between pepsinogen C and gastric carcinogenesis: a transgene and population study.
    BMC Cancer. 2023;23:520.
    PubMed     Abstract available
    
    
    
70. LI Y, Wu G, Liu J, Zhang Y, et al
    Log odds of positive lymph nodes as a novel prognostic predictor for gastric cancer: a systematic review and meta-analysis.
    BMC Cancer. 2023;23:523.
    PubMed     Abstract available
    
    
    
71. DU Y, Yu X, Chang ET, Yin L, et al
    EBV antibody and gastric cancer risk: a population-based nested case-control study in southern China.
    BMC Cancer. 2023;23:521.
    PubMed     Abstract available
    
    
    
72. ZHAO Z, Zhu Y
    FAP, CD10, and GPR77-labeled CAFs cause neoadjuvant chemotherapy resistance by inducing EMT and CSC in gastric cancer.
    BMC Cancer. 2023;23:507.
    PubMed     Abstract available
    
    
    May 2023
73. LEONG E, Ong SK, Si-Ramlee KA, Naing L, et al
    Cancer incidence and mortality in Brunei Darussalam, 2011 to 2020.
    BMC Cancer. 2023;23:466.
    PubMed     Abstract available
    
    
    
74. XU D, Liu X, Ke S, Guo Y, et al
    CCL19/CCR7 drives regulatory T cell migration and indicates poor prognosis in gastric cancer.
    BMC Cancer. 2023;23:464.
    PubMed     Abstract available
    
    
    
75. ZHANG H, Wang H, Ye L, Bao S, et al
    Comprehensive transcriptomic analyses identify KDM genes-related subtypes with different TME infiltrates in gastric cancer.
    BMC Cancer. 2023;23:454.
    PubMed     Abstract available
    
    
    
76. HAMADA T, Higashi M, Yokoyama S, Akahane T, et al
    MALAT1 functions as a transcriptional promoter of MALAT1::GLI1 fusion for truncated GLI1 protein expression in cancer.
    BMC Cancer. 2023;23:424.
    PubMed     Abstract available
    
    
    
77. YANG H, Wang JB, Wang XK, Fan JH, et al
    Association between type of drinking water and upper gastrointestinal cancer incidence in the Linxian General Population.
    BMC Cancer. 2023;23:397.
    PubMed     Abstract available
    
    
    April 2023
78. LIU Y, Shen S, Yan Z, Yan L, et al
    Expression characteristics and their functional role of IGFBP gene family in pan-cancer.
    BMC Cancer. 2023;23:371.
    PubMed     Abstract available
    
    
    
79. CUI Y, Yu Y, Zheng S, Ying J, et al
    Does resection after neoadjuvant chemotherapy of docetaxel, oxaliplatin, and S-1 (DOS regimen) benefit for gastric cancer patients with single non-curable factor? a multicenter, prospective cohort study (Neo-REGATTA).
    BMC Cancer. 2023;23:308.
    PubMed     Abstract available
    
    
    March 2023
80. WANG H, Cui H, Yang X, Peng L, et al
    TUBA1C: a new potential target of LncRNA EGFR-AS1 promotes gastric cancer progression.
    BMC Cancer. 2023;23:258.
    PubMed     Abstract available
    
    
    
81. YANG J, Li J, Deng Q, Chen Z, et al
    Effect of neoadjuvant chemotherapy combined with arterial chemoembolization on short-term clinical outcome of locally advanced gastric cancer.
    BMC Cancer. 2023;23:246.
    PubMed     Abstract available
    
    
    
82. KAMIYA H, Komatsu S, Nishibeppu K, Ohashi T, et al
    Evaluating prognostic value and stage migration effects using a positive lymph node ratio in adenocarcinoma of the esophagogastric junction.
    BMC Cancer. 2023;23:218.
    PubMed     Abstract available
    
    
    
83. ZHANG L, Wang W, Ge S, Li H, et al
    Sintilimab Plus Apatinib and Chemotherapy as Second‑/Third-Line treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a prospective, Single-Arm, phase II trial.
    BMC Cancer. 2023;23:211.
    PubMed     Abstract available
    
    
    February 2023
84. XIAO H, Bertwistle D, Khela K, Middleton-Dalby C, et al
    Global retrospective analysis of clinician- and patient-reported clinical characteristics and humanistic burden of patients with gastroesophageal cancers on first-line treatment.
    BMC Cancer. 2023;23:186.
    PubMed     Abstract available
    
    
    
85. LAM LL, Pavlakis N, Shitara K, Sjoquist KM, et al
    INTEGRATE II: randomised phase III controlled trials of regorafenib containing regimens versus standard of care in refractory Advanced Gastro-Oesophageal Cancer (AGOC): a study by the Australasian Gastro-Intestinal Trials Group (AGITG).
    BMC Cancer. 2023;23:180.
    PubMed     Abstract available
    
    
    
86. STIEFEL R, Lehmann K, Winder T, Siebenhuner AR, et al
    What have we learnt from the past - would treatment decisions for GEP-NET patients differ between 2012 to 2016 by the new recommendations in 2022?
    BMC Cancer. 2023;23:148.
    PubMed     Abstract available
    
    
    
87. HUO G, Liu W, Chen P
    Efficacy of PD-1/PD-L1 inhibitors in gastric or gastro-oesophageal junction cancer based on clinical characteristics: a meta-analysis.
    BMC Cancer. 2023;23:143.
    PubMed     Abstract available
    
    
    January 2023
88. ZHOU Z, Guo S, Lai S, Wang T, et al
    Integrated single-cell and bulk RNA sequencing analysis identifies a cancer-associated fibroblast-related gene signature for predicting survival and therapy in gastric cancer.
    BMC Cancer. 2023;23:108.
    PubMed     Abstract available
    
    
    
89. DONG C, Luan F, Tian W, Duan K, et al
    Identification and validation of crucial lnc-TRIM28-14 and hub genes promoting gastric cancer peritoneal metastasis.
    BMC Cancer. 2023;23:76.
    PubMed     Abstract available
    
    
    
90. YANG J, Su H, Chen T, Chen X, et al
    Development and validation of nomogram of peritoneal metastasis in gastric cancer based on simplified clinicopathological features and serum tumor markers.
    BMC Cancer. 2023;23:64.
    PubMed     Abstract available
    
    
    
91. YANG X, Wang A, Li J, Zhou K, et al
    Prognostic significance of preoperative serum tumor markers in hepatoid adenocarcinoma of stomach (HAS).
    BMC Cancer. 2023;23:53.
    PubMed     Abstract available
    
    
    
92. LIANG XW, Xiao WS, Lei H, Huag QC, et al
    Risk model and factors for prediction of response to neoadjuvant chemotherapy in patients with advanced gastric cancer-a two-center cohort study.
    BMC Cancer. 2023;23:41.
    PubMed     Abstract available
    
    
    
93. LI L, Huang X, Zhang S, Zhan Z, et al
    Rapid and label-free detection of gastrointestinal stromal tumor via a combination of two-photon microscopy and imaging analysis.
    BMC Cancer. 2023;23:38.
    PubMed     Abstract available
    
    
    
94. ZHANG R, Hu C, Zhang J, Zhang Y, et al
    Prognostic significance of inflammatory and nutritional markers in perioperative period for patients with advanced gastric cancer.
    BMC Cancer. 2023;23:5.
    PubMed     Abstract available
    
    
    December 2022
95. DAY F, Sridharan S, Lynam J, Gedye C, et al
    Chemoradiotherapy with concurrent durvalumab for the palliative treatment of oligometastatic oesophageal and gastrooesophageal carcinoma with dysphagia: a single arm phase II clinical trial (PALEO, sponsored by the Australasian Gastro-Intestinal Trial
    BMC Cancer. 2022;22:1324.
    PubMed     Abstract available
    
    
    
96. WANG Y, Lei X, Shan F, Li S, et al
    Safety and short-term outcomes of gastrectomy after preoperative chemotherapy plus immunotherapy versus preoperative chemotherapy: a retrospective cohort study.
    BMC Cancer. 2022;22:1306.
    PubMed     Abstract available
    
    
    
97. TERASHIMA T, Konishi H, Sato Y, Igarashi M, et al
    Impact of coronavirus disease 2019 on the number of newly diagnosed cancer patients and examinations and surgeries performed for cancer in Japan: a nationwide study.
    BMC Cancer. 2022;22:1303.
    PubMed     Abstract available
    
    
    November 2022
98. DU Y, Chen Y, Wu T, Fan X, et al
    Correction: miR-2682-3p antagonizes its host lncRNA-MIR137HG by interacting with the same target FUS to regulate the progression of gastric cancer.
    BMC Cancer. 2022;22:1234.
    PubMed    
    
    
    
99. ZHANG C, Wu B, Yang H, Yao Z, et al
    The validity of neoadjuvant chemotherapy with paclitaxel plus S-1 is not inferior to that of SOX regimen for locally advanced gastric cancer: an observational study.
    BMC Cancer. 2022;22:1223.
    PubMed     Abstract available
    
    
    
100. SUN H, Wang X, Zhang X, Wang X, et al
     Multiplexed immunofluorescence analysis of CAF-markers, EZH2 and FOXM1 in gastric tissue: associations with clinicopathological parameters and clinical outcomes.
     BMC Cancer. 2022;22:1188.
     PubMed     Abstract available
     
     
     
101. YANG T, Xu R, You J, Li F, et al
     Prognostic and clinical significance of HER-2 low expression in early-stage gastric cancer.
     BMC Cancer. 2022;22:1168.
     PubMed     Abstract available
     
     
     
102. XU M, Qiao X, Li L, Liu S, et al
     Application of preoperative CT texture analysis in papillary gastric adenocarcinoma.
     BMC Cancer. 2022;22:1161.
     PubMed     Abstract available
     
     
     
103. WEI C, Li C, Chen X, Chen G, et al
     Development and verification of a nomogram for predicting the prognosis of resectable gastric cancer with outlet obstruction.
     BMC Cancer. 2022;22:1154.
     PubMed     Abstract available
     
     
     
104. ZHANG X, Xu S, Wang J, Lv Y, et al
     Are anti-PD-1-associated immune related adverse events a harbinger of favorable clinical prognosis in patients with gastric cancer?
     BMC Cancer. 2022;22:1136.
     PubMed     Abstract available
     
     
     
105. KATTAN J, Karak FE, Farhat F, Gerges DA, et al
     Prevalence of Her2-neu status and its clinicopathological association in newly diagnosed gastric cancer patients.
     BMC Cancer. 2022;22:1114.
     PubMed     Abstract available
     
     
     October 2022
106. LIANG J, Dai W, Li Z, Liang X, et al
     Evaluating the efficacy and microenvironment changes of HER2 + gastric cancer during HLX02 and Endostar treatment using quantitative MRI.
     BMC Cancer. 2022;22:1033.
     PubMed     Abstract available
     
     
     
107. LAI MY, Kang SY, Sun YT, Quan TT, et al
     Comparison of response evaluation criteria in solid tumors and tumor regression grade in evaluating the effect of preoperative systemic therapy of gastric cancer.
     BMC Cancer. 2022;22:1031.
     PubMed     Abstract available
     
     
     September 2022
108. DONG C, Sun J, Ma S, Zhang G, et al
     Retraction Note: K-ras-ERK1/2 down-regulates H2A.X(Y142ph) through WSTF to promote the progress of gastric cancer.
     BMC Cancer. 2022;22:959.
     PubMed    
     
     
     
109. LI Y, Zhao J, Chen R, Chen S, et al
     Integration of clinical and transcriptomics reveals programming of the lipid metabolism in gastric cancer.
     BMC Cancer. 2022;22:955.
     PubMed     Abstract available
     
     
     
110. KIM TH, Ahn MS, Choi YW, Kang SY, et al
     Analysis of treatment outcomes according to the cycles of adjuvant chemotherapy in gastric cancer: a retrospective nationwide cohort study.
     BMC Cancer. 2022;22:948.
     PubMed     Abstract available
     
     
     August 2022
111. LIN Z, Zeng H, Xiong W, Li J, et al
     Whether the infracardiac bursa protect right pleura during laparoscopic radical operation of Siewert type II adenocarcinoma of esophagogastric junction?
     BMC Cancer. 2022;22:927.
     PubMed     Abstract available
     
     
     
112. XU H, Zhang H, Guo W, Zhong X, et al
     Safety and efficacy profile of Trastuzumab deruxtecan in solid cancer: pooled reanalysis based on clinical trials.
     BMC Cancer. 2022;22:923.
     PubMed     Abstract available
     
     
     
113. CHE H, Xiong Q, Ma J, Chen S, et al
     Association of Helicobacter pylori infection with survival outcomes in advanced gastric cancer patients treated with immune checkpoint inhibitors.
     BMC Cancer. 2022;22:904.
     PubMed     Abstract available
     
     
     
114. NGUYEN MT, Huynh NNY, Nguyen DD, Ta NH, et al
     Vitamin D intake and gastric cancer in Viet Nam: a case-control study.
     BMC Cancer. 2022;22:838.
     PubMed     Abstract available
     
     
     July 2022
115. ENDO S, Terazawa T, Goto M, Tanaka R, et al
     Neoadjuvant docetaxel, oxaliplatin and S-1 therapy for the patients with large type 3 or type 4 gastric cancer (OGSG1902): protocol of a multi-center, phase II study.
     BMC Cancer. 2022;22:811.
     PubMed     Abstract available
     
     
     
116. LE HX, Truong DTT, Tran LB, Le PH, et al
     A prospective cohort study on the association between waterpipe tobacco smoking and gastric cancer mortality in Northern Vietnam.
     BMC Cancer. 2022;22:803.
     PubMed     Abstract available
     
     
     
117. NAM S, Lee Y, Kim JH
     RHOA protein expression correlates with clinical features in gastric cancer: a systematic review and meta-analysis.
     BMC Cancer. 2022;22:798.
     PubMed     Abstract available
     
     
     
118. YAMAGUCHI T, Kawakami H, Sakai D, Kurokawa Y, et al
     Protocol of OGSG 1901: a phase II trial of ramucirumab plus irinotecan for patients with early relapsed gastric cancer during or after adjuvant docetaxel plus S - 1 therapy.
     BMC Cancer. 2022;22:773.
     PubMed     Abstract available
     
     
     
119. HE XJ, Ma YY, Yu S, Jiang XT, et al
     Retraction Note: Up-regulated miR-199a-5p in gastric cancer functions as an oncogene and targets klotho.
     BMC Cancer. 2022;22:766.
     PubMed    
     
     
     
120. YAN Y, Ma Z, Ji X, Liu J, et al
     A potential decision-making algorithm based on endoscopic ultrasound for staging early gastric cancer: a retrospective study.
     BMC Cancer. 2022;22:761.
     PubMed     Abstract available
     
     
     
121. XU S, Chen W, Wang Y, Zhang Y, et al
     N6-methyladenosine-related lncRNAs identified as potential biomarkers for predicting the overall survival of Asian gastric cancer patients.
     BMC Cancer. 2022;22:721.
     PubMed     Abstract available
     
     
     June 2022
122. ZHOU M, Yang W, Xuan Y, Zou W, et al
     A study protocol of a randomized phase II trial of perioperative chemoimmunotherapy verses perioperative chemoimmunotherapy plus preoperative chemoradiation for locally advanced gastric (G) or gastroesophageal junction (GEJ) adenocarcinoma: the NeoRac
     BMC Cancer. 2022;22:710.
     PubMed     Abstract available
     
     
     
123. UCARYILMAZ METIN C, Ozcan G
     Comprehensive bioinformatic analysis reveals a cancer-associated fibroblast gene signature as a poor prognostic factor and potential therapeutic target in gastric cancer.
     BMC Cancer. 2022;22:692.
     PubMed     Abstract available
     
     
     
124. DU Y, Chen Y, Wu T, Fan X, et al
     miR-2682-3p antagonizes its host lncRNA-MIR137HG by interacting with the same target FUS to regulate the progression of gastric cancer.
     BMC Cancer. 2022;22:689.
     PubMed     Abstract available
     
     
     
125. ZHANG X, Wang D, Sun T, Li W, et al
     Advanced lung cancer inflammation index (ALI) predicts prognosis of patients with gastric cancer after surgical resection.
     BMC Cancer. 2022;22:684.
     PubMed     Abstract available
     
     
     
126. VAN SCHOOTEN TS, Derks S, Jimenez-Marti E, Carneiro F, et al
     The LEGACy study: a European and Latin American consortium to identify risk factors and molecular phenotypes in gastric cancer to improve prevention strategies and personalized clinical decision making globally.
     BMC Cancer. 2022;22:646.
     PubMed     Abstract available
     
     
     
127. MIYATANI K, Sawata S, Makinoya M, Miyauchi W, et al
     Combined analysis of preoperative and postoperative lymphocyte-C-reactive protein ratio precisely predicts outcomes of patients with gastric cancer.
     BMC Cancer. 2022;22:641.
     PubMed     Abstract available
     
     
     
128. WANG Y, Fang T, Wang Y, Yin X, et al
     Impact of AADAC gene expression on prognosis in patients with Borrmann type III advanced gastric cancer.
     BMC Cancer. 2022;22:635.
     PubMed     Abstract available
     
     
     
129. KINOSHITA J, Fushida S, Yamaguchi T, Moriyama H, et al
     Prognostic value of tumor-infiltrating CD163(+)macrophage in patients with metastatic gastric cancer undergoing multidisciplinary treatment.
     BMC Cancer. 2022;22:608.
     PubMed     Abstract available
     
     
     
130. TSUJIO G, Maruo K, Yamamoto Y, Sera T, et al
     Significance of tumor heterogeneity of p-Smad2 and c-Met in HER2-positive gastric carcinoma with lymph node metastasis.
     BMC Cancer. 2022;22:598.
     PubMed     Abstract available
     
     
     May 2022
131. MATSUNAGA T, Saito H, Osaki T, Takahashi S, et al
     Impact of geriatric nutritional risk index on outcomes after gastrectomy in elderly patients with gastric cancer: a retrospective multicenter study in Japan.
     BMC Cancer. 2022;22:540.
     PubMed     Abstract available
     
     
     
132. DOS SANTOS M, Lequesne J, Leconte A, Corbinais S, et al
     Perioperative treatment in resectable gastric cancer with spartalizumab in combination with fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): a phase II study (GASPAR).
     BMC Cancer. 2022;22:537.
     PubMed     Abstract available
     
     
     April 2022
133. KOOPAIE M, Ghafourian M, Manifar S, Younespour S, et al
     Evaluation of CSTB and DMBT1 expression in saliva of gastric cancer patients and controls.
     BMC Cancer. 2022;22:473.
     PubMed     Abstract available
     
     
     
134. TAN Y, Chen Q, Pan S, An W, et al
     LMOD1, an oncogene associated with Lauren classification, regulates the metastasis of gastric cancer cells through the FAK-AKT/mTOR pathway.
     BMC Cancer. 2022;22:474.
     PubMed     Abstract available
     
     
     
135. CHINEN T, Sasabuchi Y, Matsui H, Yamaguchi H, et al
     Oxaliplatin- versus cisplatin-based regimens for elderly individuals with advanced gastric cancer: a retrospective cohort study.
     BMC Cancer. 2022;22:460.
     PubMed     Abstract available
     
     
     
136. DALHAMMAR K, Kristensson J, Falkenback D, Rasmussen BH, et al
     Symptoms, problems and quality of life in patients newly diagnosed with oesophageal and gastric cancer - a comparative study of treatment strategy.
     BMC Cancer. 2022;22:434.
     PubMed     Abstract available
     
     
     
137. LI PC, Huang RY, Yang YC, Hsieh KP, et al
     Prognostic impact of angiotensin-converting enzyme inhibitors and angiotensin receptors blockers in esophageal or gastric cancer patients with hypertension - a real-world study.
     BMC Cancer. 2022;22:430.
     PubMed     Abstract available
     
     
     
138. SHIN J, Shin DW, Lee J, Hwang J, et al
     Exploring socio-demographic, physical, psychological, and quality of life-related factors related with fear of cancer recurrence in stomach cancer survivors: a cross-sectional study.
     BMC Cancer. 2022;22:414.
     PubMed     Abstract available
     
     
     
139. MATSUNAGA T, Saito H, Kuroda H, Osaki T, et al
     CA19-9 in combination with P-CRP as a predictive marker of immune-related adverse events in patients with recurrent or unresectable advanced gastric cancer treated with nivolumab.
     BMC Cancer. 2022;22:418.
     PubMed     Abstract available
     
     
     
140. KIM JH, Ryu MH, Park YS, Ma J, et al
     Predictive biomarkers for the efficacy of nivolumab as >/= 3(rd)-line therapy in patients with advanced gastric cancer: a subset analysis of ATTRACTION-2 phase III trial.
     BMC Cancer. 2022;22:378.
     PubMed     Abstract available
     
     
     
141. LEI L, Li N, Yuan P, Liu D, et al
     A new risk model based on a 11-m(6)A-related lncRNA signature for predicting prognosis and monitoring immunotherapy for gastric cancer.
     BMC Cancer. 2022;22:365.
     PubMed     Abstract available
     
     
     March 2022
142. WANG Y, Zhu GQ, Tian D, Zhou CW, et al
     Comprehensive analysis of tumor immune microenvironment and prognosis of m6A-related lncRNAs in gastric cancer.
     BMC Cancer. 2022;22:316.
     PubMed     Abstract available
     
     
     
143. GOTO K, Morimoto M, Osaki M, Tanio A, et al
     The impact of AMIGO2 on prognosis and hepatic metastasis in gastric cancer patients.
     BMC Cancer. 2022;22:280.
     PubMed     Abstract available
     
     
     
144. EBERT K, Haffner I, Zwingenberger G, Keller S, et al
     Combining gene expression analysis of gastric cancer cell lines and tumor specimens to identify biomarkers for anti-HER therapies-the role of HAS2, SHB and HBEGF.
     BMC Cancer. 2022;22:254.
     PubMed     Abstract available
     
     
     
145. JIANG Z, Zhou A, Sun Y, Zhang W, et al
     Biweekly oxaliplatin plus S1 for Chinese elderly patients with advanced gastric or gastroesophageal junction cancer as the first-line therapy: a single-arm, phase 2 study.
     BMC Cancer. 2022;22:253.
     PubMed     Abstract available
     
     
     
146. CHU XD, Lin ZB, Huang T, Ding H, et al
     Thrombospondin-2 holds prognostic value and is associated with metastasis and the mismatch repair process in gastric cancer.
     BMC Cancer. 2022;22:250.
     PubMed     Abstract available
     
     
     February 2022
147. LI N, Xiang X, Zhao D, Wang X, et al
     Preoperative versus postoperative chemo-radiotherapy for locally advanced gastric cancer: a multicenter propensity score-matched analysis.
     BMC Cancer. 2022;22:212.
     PubMed     Abstract available
     
     
     
148. JIA Z, Zheng M, Jiang J, Cao D, et al
     Positive H. pylori status predicts better prognosis of non-cardiac gastric cancer patients: results from cohort study and meta-analysis.
     BMC Cancer. 2022;22:155.
     PubMed     Abstract available
     
     
     
149. BRODSKY AS, Khurana J, Guo KS, Wu EY, et al
     Somatic mutations in collagens are associated with a distinct tumor environment and overall survival in gastric cancer.
     BMC Cancer. 2022;22:139.
     PubMed     Abstract available
     
     
     January 2022
150. LIN L, Li H, Shi D, Liu Z, et al
     Depletion of C12orf48 inhibits gastric cancer growth and metastasis via up-regulating Poly r(C)-Binding Protein (PCBP) 1.
     BMC Cancer. 2022;22:123.
     PubMed     Abstract available
     
     
     
151. SCHLINTL V, Huemer F, Rinnerthaler G, Melchardt T, et al
     Checkpoint inhibitors in metastatic gastric and GEJ cancer: a multi-institutional retrospective analysis of real-world data in a Western cohort.
     BMC Cancer. 2022;22:51.
     PubMed     Abstract available
     
     
     
152. SANO A, Sohda M, Nakazawa N, Ubukata Y, et al
     Clinical features as potential prognostic factors in patients treated with nivolumab for highly pretreated metastatic gastric cancer: a multicenter retrospective study.
     BMC Cancer. 2022;22:22.
     PubMed     Abstract available
     
     
     
153. HENNESSY MA, Hamid M, Keegan NM, Corrigan L, et al
     Metastatic gastroesophageal cancer in older patients - is this patient cohort represented in clinical trials?
     BMC Cancer. 2022;22:3.
     PubMed     Abstract available
     
     
     December 2021
154. SHI M, Yang Z, Lu S, Liu W, et al
     Oxaliplatin plus S-1 with intraperitoneal paclitaxel for the treatment of Chinese advanced gastric cancer with peritoneal metastases.
     BMC Cancer. 2021;21:1344.
     PubMed     Abstract available
     
     
     
155. CHEN Y, He J, Liu D, Xiao J, et al
     Triplet versus doublet neoadjuvant chemotherapy regimens for locally advanced gastric cancer: a propensity score matching analysis.
     BMC Cancer. 2021;21:1328.
     PubMed     Abstract available
     
     
     
156. MA T, Wu Z, Zhang X, Xu H, et al
     Development and validation of a prognostic scoring model for mortality risk stratification in patients with recurrent or metastatic gastric carcinoma.
     BMC Cancer. 2021;21:1326.
     PubMed     Abstract available
     
     
     
157. ZHANG S, Lv M, Cheng Y, Wang S, et al
     Immune landscape of advanced gastric cancer tumor microenvironment identifies immunotherapeutic relevant gene signature.
     BMC Cancer. 2021;21:1324.
     PubMed     Abstract available
     
     
     
158. SAITO H, Shimizu S, Shishido Y, Miyatani K, et al
     Prognostic significance of the combination of preoperative red cell distribution width and platelet distribution width in patients with gastric cancer.
     BMC Cancer. 2021;21:1317.
     PubMed     Abstract available
     
     
     
159. HAN C, Zhang C, Wang H, Li K, et al
     Angiogenesis-related lncRNAs predict the prognosis signature of stomach adenocarcinoma.
     BMC Cancer. 2021;21:1312.
     PubMed     Abstract available
     
     
     
160. JIANG L, Zhang Y, Guo L, Liu C, et al
     Exosomal microRNA-107 reverses chemotherapeutic drug resistance of gastric cancer cells through HMGA2/mTOR/P-gp pathway.
     BMC Cancer. 2021;21:1290.
     PubMed     Abstract available
     
     
     
161. XU X, Wang S, Wang H, Pan C, et al
     Hsa_circ_0008434 regulates USP9X expression by sponging miR-6838-5p to promote gastric cancer growth, migration and invasion.
     BMC Cancer. 2021;21:1289.
     PubMed     Abstract available
     
     
     November 2021
162. YANZHANG W, Guanghua L, Zhihao Z, Zhixiong W, et al
     The risk of lymph node metastasis in gastric cancer conforming to indications of endoscopic resection and pylorus-preserving gastrectomy: a single-center retrospective study.
     BMC Cancer. 2021;21:1280.
     PubMed     Abstract available
     
     
     
163. SUNDE B, Lindblad M, Malmstrom M, Hedberg J, et al
     Health-related quality of life one year after the diagnosis of oesophageal cancer: a population-based study from the Swedish National Registry for Oesophageal and Gastric Cancer.
     BMC Cancer. 2021;21:1277.
     PubMed     Abstract available
     
     
     
164. KINAMI S, Nakamura N, Miyashita T, Kitakata H, et al
     nPTD classification: an updated classification of gastric cancer location for function preserving gastrectomy based on physiological lymphatic flow.
     BMC Cancer. 2021;21:1231.
     PubMed     Abstract available
     
     
     
165. MATSUNAGA T, Saito H, Miyauchi W, Shishido Y, et al
     Impact of skeletal muscle mass in patients with unresectable gastric cancer who received palliative first-line chemotherapy based on 5-fluorouracil.
     BMC Cancer. 2021;21:1219.
     PubMed     Abstract available
     
     
     
166. WEI J, Zeng Y, Gao X, Liu T, et al
     A novel ferroptosis-related lncRNA signature for prognosis prediction in gastric cancer.
     BMC Cancer. 2021;21:1221.
     PubMed     Abstract available
     
     
     
167. WU WW, Zhang WH, Zhang WY, Liu K, et al
     The long-term survival outcomes of gastric cancer patients with total intravenous anesthesia or inhalation anesthesia: a single-center retrospective cohort study.
     BMC Cancer. 2021;21:1193.
     PubMed     Abstract available
     
     
     
168. CHEN S, Lai H, Zhao J, Chen B, et al
     The viral expression and immune status in human cancers and insights into novel biomarkers of immunotherapy.
     BMC Cancer. 2021;21:1183.
     PubMed     Abstract available
     
     
     October 2021
169. LIU R, Yang X
     LncRNA LINC00342 promotes gastric cancer progression by targeting the miR-545-5p/CNPY2 axis.
     BMC Cancer. 2021;21:1163.
     PubMed     Abstract available
     
     
     
170. GOTZE TO, Piso P, Lorenzen S, Bankstahl US, et al
     Preventive HIPEC in combination with perioperative FLOT versus FLOT alone for resectable diffuse type gastric and gastroesophageal junction type II/III adenocarcinoma - the phase III "PREVENT"- (FLOT9) trial of the AIO /CAOGI /ACO.
     BMC Cancer. 2021;21:1158.
     PubMed     Abstract available
     
     
     
171. WANG Q, Zhong J, Huang Q, Chen Z, et al
     A survival comparison of gastric mucin-producing adenocarcinoma to conventional adenocarcinoma: a SEER database analysis.
     BMC Cancer. 2021;21:1138.
     PubMed     Abstract available
     
     
     
172. GIOMMONI E, Lavacchi D, Tirino G, Fornaro L, et al
     Results of the observational prospective RealFLOT study.
     BMC Cancer. 2021;21:1086.
     PubMed     Abstract available
     
     
     
173. HIRAHARA N, Matsubara T, Kaji S, Yamamoto T, et al
     Phase II feasibility study of adjuvant chemotherapy with docetaxel/cisplatin/S-1 followed by S-1 for stage III gastric cancer.
     BMC Cancer. 2021;21:1073.
     PubMed     Abstract available
     
     
     September 2021
174. JIANG Q, Chen H, Tang Z, Sun J, et al
     Stemness-related LncRNA pair signature for predicting therapy response in gastric cancer.
     BMC Cancer. 2021;21:1067.
     PubMed     Abstract available
     
     
     
175. YURA M, Yoshikawa T, Wada T, Otsuki S, et al
     The prognostic impact of macroscopic serosal change on resectable advanced gastric cancer.
     BMC Cancer. 2021;21:1056.
     PubMed     Abstract available
     
     
     
176. LIU S, Xu M, Qiao X, Ji C, et al
     Prediction of serosal invasion in gastric cancer: development and validation of multivariate models integrating preoperative clinicopathological features and radiographic findings based on late arterial phase CT images.
     BMC Cancer. 2021;21:1038.
     PubMed     Abstract available
     
     
     
177. CORDOVA-DELGADO M, Bravo ML, Cumsille E, Hill CN, et al
     A case-control study of a combination of single nucleotide polymorphisms and clinical parameters to predict clinically relevant toxicity associated with fluoropyrimidine and platinum-based chemotherapy in gastric cancer.
     BMC Cancer. 2021;21:1030.
     PubMed     Abstract available
     
     
     
178. PARK SH, Suh YS, Kim TH, Choi YH, et al
     Postoperative morbidity and quality of life between totally laparoscopic total gastrectomy and laparoscopy-assisted total gastrectomy: a propensity-score matched analysis.
     BMC Cancer. 2021;21:1016.
     PubMed     Abstract available
     
     
     August 2021
179. CHEN L, Zhang C, Yao Z, Cui M, et al
     Adjuvant chemotherapy is an additional option for locally advanced gastric cancer after radical gastrectomy with D2 lymphadenectomy: a retrospective control study.
     BMC Cancer. 2021;21:974.
     PubMed     Abstract available
     
     
     
180. LI HQ, Xue H, Yuan H, Wan GY, et al
     Preferences of first-degree relatives of gastric cancer patients for gastric cancer screening: a discrete choice experiment.
     BMC Cancer. 2021;21:959.
     PubMed     Abstract available
     
     
     
181. UOZUMI T, Sumiyoshi T, Tomita Y, Tokuchi K, et al
     Does second-look endoscopy reduce the bleeding after gastric endoscopic submucosal dissection for patients receiving antithrombotic therapy?
     BMC Cancer. 2021;21:946.
     PubMed     Abstract available
     
     
     
182. NING G, Zhu Q, Kang W, Lee H, et al
     A novel treatment strategy for lapatinib resistance in a subset of HER2-amplified gastric cancer.
     BMC Cancer. 2021;21:923.
     PubMed     Abstract available
     
     
     
183. WANG J, Xu P, Hao Y, Yu T, et al
     Interaction between DNMT3B and MYH11 via hypermethylation regulates gastric cancer progression.
     BMC Cancer. 2021;21:914.
     PubMed     Abstract available
     
     
     July 2021
184. YEN CC, Shan YS, Chao YJ, Liao TK, et al
     Surgery alone, adjuvant tegafur/gimeracil/octeracil (S-1), or platinum-based chemotherapies for resectable gastric cancer: real-world experience and a propensity score matching analysis.
     BMC Cancer. 2021;21:796.
     PubMed     Abstract available
     
     
     
185. ZHOU YJ, Lu XF, Meng JL, Wang XY, et al
     Neo-adjuvant radiation therapy provides a survival advantage in T3-T4 nodal positive gastric and gastroesophageal junction adenocarcinoma: a SEER database analysis.
     BMC Cancer. 2021;21:771.
     PubMed     Abstract available
     
     
     June 2021
186. SANTERO M, Perez-Bracchiglione J, Acosta-Dighero R, Meade AG, et al
     Efficacy of systemic oncological treatments in patients with advanced esophageal or gastric cancers at high risk of dying in the middle and short term: an overview of systematic reviews.
     BMC Cancer. 2021;21:712.
     PubMed     Abstract available
     
     
     
187. YE Z, Zeng Y, Wei S, Wang Y, et al
     Short-term survival and safety of apatinib combined with oxaliplatin and S-1 in the conversion therapy of unresectable gastric cancer.
     BMC Cancer. 2021;21:702.
     PubMed     Abstract available
     
     
     
188. LU XQ, Zhang JQ, Zhang SX, Qiao J, et al
     Identification of novel hub genes associated with gastric cancer using integrated bioinformatics analysis.
     BMC Cancer. 2021;21:697.
     PubMed     Abstract available
     
     
     
189. WU R, Guo S, Lai S, Pan G, et al
     A stable gene set for prediction of prognosis and efficacy of chemotherapy in gastric cancer.
     BMC Cancer. 2021;21:684.
     PubMed     Abstract available
     
     
     
190. ZHANG J, Lv W, Liu Y, Fu W, et al
     LINC_00355 promotes gastric cancer progression by upregulating PHF19 expression through sponging miR-15a-5p.
     BMC Cancer. 2021;21:657.
     PubMed     Abstract available
     
     
     May 2021
191. DAI J, Nishi A, Li ZX, Zhang Y, et al
     DNA methylation signatures associated with prognosis of gastric cancer.
     BMC Cancer. 2021;21:610.
     PubMed     Abstract available
     
     
     
192. RUSTGI SD, Oh A, Yang JY, Kang D, et al
     Initiation of Somatostatin analogues for neuroendocrine tumor patients: a cost-effectiveness analysis.
     BMC Cancer. 2021;21:597.
     PubMed     Abstract available
     
     
     
193. CHEN Y, Hu N, Liao L, Yu K, et al
     ABO genotypes and the risk of esophageal and gastric cancers.
     BMC Cancer. 2021;21:589.
     PubMed     Abstract available
     
     
     
194. O'CONNOR L, Smyth E, Bennett AE, Smith V, et al
     Identifying outcomes reported in exercise interventions in oesophagogastric cancer survivors: a systematic review.
     BMC Cancer. 2021;21:586.
     PubMed     Abstract available
     
     
     
195. CHUN SH, Kim EY, Yoon JS, Won HS, et al
     Prognostic value of noggin protein expression in patients with resected gastric cancer.
     BMC Cancer. 2021;21:558.
     PubMed     Abstract available
     
     
     
196. NIE C, Han X, Wei R, Leonteva A, et al
     Association of ZNF331 and WIF1 methylation in peripheral blood leukocytes with the risk and prognosis of gastric cancer.
     BMC Cancer. 2021;21:551.
     PubMed     Abstract available
     
     
     
197. CHEN J, Xia YJ, Liu TY, Lai YH, et al
     Development and validation of a survival nomogram for patients with Siewert type II/III adenocarcinoma of the esophagogastric junction based on real-world data.
     BMC Cancer. 2021;21:532.
     PubMed     Abstract available
     
     
     April 2021
198. LIU N, Wu Y, Cheng W, Wu Y, et al
     Identification of novel prognostic biomarkers by integrating multi-omics data in gastric cancer.
     BMC Cancer. 2021;21:460.
     PubMed     Abstract available
     
     
     
199. ZHONG X, Xuan F, Qian Y, Pan J, et al
     A genomic-clinicopathologic Nomogram for the preoperative prediction of lymph node metastasis in gastric cancer.
     BMC Cancer. 2021;21:455.
     PubMed     Abstract available
     
     
     
200. LIU L, Zhang C, Wang J, Liu X, et al
     A high level of lncFGD5-AS1 inhibits epithelial-to-Mesenchymal transition by regulating the miR-196a-5p/SMAD6/BMP axis in gastric Cancer.
     BMC Cancer. 2021;21:453.
     PubMed     Abstract available
     
     
     
201. YU J, Jung J, Park SR, Ryu MH, et al
     Role of palliative radiotherapy in bleeding control in patients with unresectable advanced gastric cancer.
     BMC Cancer. 2021;21:413.
     PubMed     Abstract available
     
     
     
202. YU Y, Xie Z, Zhao M, Lian X, et al
     Identification of PIK3CA multigene mutation patterns associated with superior prognosis in stomach cancer.
     BMC Cancer. 2021;21:368.
     PubMed     Abstract available
     
     
     March 2021
203. KIM TH, Do Cho H, Choi YW, Lee HW, et al
     Trastuzumab-based palliative chemotherapy for HER2-positive gastric cancer: a single-center real-world data.
     BMC Cancer. 2021;21:325.
     PubMed     Abstract available
     
     
     
204. CAI Z, Song H, Fingerhut A, Sun J, et al
     A greater lymph node yield is required during pathological examination in microsatellite instability-high gastric cancer.
     BMC Cancer. 2021;21:319.
     PubMed     Abstract available
     
     
     
205. LIANG Y, Zhao L, Chen H, Lin T, et al
     Correction to: Survival analysis of elderly patients over 65 years old with stage II/III gastric cancer treated with adjuvant chemotherapy after laparoscopic D2 gastrectomy: a retrospective cohort study.
     BMC Cancer. 2021;21:298.
     PubMed    
     
     
     
206. JI J, Chen J, Wang A, Zhang W, et al
     KK-LC-1 may be an effective prognostic biomarker for gastric cancer.
     BMC Cancer. 2021;21:267.
     PubMed     Abstract available
     
     
     
207. SATO A, Matsubayashi K, Morishima T, Nakata K, et al
     Increasing trends in the prevalence of prior cancer in newly diagnosed lung, stomach, colorectal, breast, cervical, and corpus uterine cancer patients: a population-based study.
     BMC Cancer. 2021;21:264.
     PubMed     Abstract available
     
     
     
208. HE P, Cheng S, Hu F, Ma Z, et al
     Up-regulation of DGAT1 in cancer tissues and tumor-infiltrating macrophages influenced survival of patients with gastric cancer.
     BMC Cancer. 2021;21:252.
     PubMed     Abstract available
     
     
     
209. GE Y, Wei F, Du G, Fei G, et al
     The association of sex-biased ATRX mutation in female gastric cancer patients with enhanced immunotherapy-related anticancer immunity.
     BMC Cancer. 2021;21:240.
     PubMed     Abstract available
     
     
     
210. OKAGAWA Y, Sumiyoshi T, Kondo H, Tomita Y, et al
     Comparison of clinicopathological features and long-term prognosis between mixed predominantly differentiated-type and pure differentiated-type early gastric cancer.
     BMC Cancer. 2021;21:235.
     PubMed     Abstract available
     
     
     
211. EHARA T, Uehara T, Nakajima T, Kinugawa Y, et al
     LGR5 expression is associated with prognosis in poorly differentiated gastric adenocarcinoma.
     BMC Cancer. 2021;21:228.
     PubMed     Abstract available
     
     
     
212. FAN B, Bu Z, Zhang J, Zong X, et al
     Phase II trial of prophylactic hyperthermic intraperitoneal chemotherapy in patients with locally advanced gastric cancer after curative surgery.
     BMC Cancer. 2021;21:216.
     PubMed     Abstract available
     
     
     
213. LIM JH, Song JH, Chung SJ, Chung GE, et al
     Characteristics of interval gastric neoplasms detected within two years after negative screening endoscopy among Koreans.
     BMC Cancer. 2021;21:218.
     PubMed     Abstract available
     
     
     February 2021
214. LIANG Y, Zhao L, Chen H, Lin T, et al
     Survival analysis of elderly patients over 65 years old with stage II/III gastric cancer treated with adjuvant chemotherapy after laparoscopic D2 gastrectomy: a retrospective cohort study.
     BMC Cancer. 2021;21:196.
     PubMed     Abstract available
     
     
     
215. CHEN XJ, Chen GM, Wei YC, Yu H, et al
     Palliative Gastrectomy versus Gastrojejunostomy for advanced Gastric cancer with outlet obstruction: a propensity score matching analysis.
     BMC Cancer. 2021;21:188.
     PubMed     Abstract available
     
     
     
216. KIM KW, Lee K, Lee JB, Park T, et al
     Preoperative nutritional risk index and postoperative one-year skeletal muscle loss can predict the prognosis of patients with gastric adenocarcinoma: a registry-based study.
     BMC Cancer. 2021;21:157.
     PubMed     Abstract available
     
     
     
217. BAEG K, Harris C, Naparst MS, Ahn E, et al
     Effect of treatment center volume on outcomes in gastroenteropancreatic neuroendocrine tumor patients.
     BMC Cancer. 2021;21:146.
     PubMed     Abstract available
     
     
     January 2021
218. ITO A, Kagawa S, Sakamoto S, Kuwada K, et al
     Extracellular vesicles shed from gastric cancer mediate protumor macrophage differentiation.
     BMC Cancer. 2021;21:102.
     PubMed     Abstract available
     
     
     
219. OKUBO K, Arigami T, Matsushita D, Kijima T, et al
     Clinical impact of creatine phosphokinase and c-reactive protein as predictors of postgastrectomy complications in patients with gastric cancer.
     BMC Cancer. 2021;21:95.
     PubMed     Abstract available
     
     
     
220. EMBAYE KS, Zhang C, Ghebrehiwet MA, Wang Z, et al
     Clinico-pathologic determinants of non-e-curative outcome following en-bloc endoscopic submucosal dissection in patients with early gastric neoplasia.
     BMC Cancer. 2021;21:92.
     PubMed     Abstract available
     
     
     
221. CHENG X, Wu D, Xu N, Chen L, et al
     Adjuvant albumin-bound paclitaxel combined with S-1 vs. oxaliplatin combined with capecitabine after D2 gastrectomy in patients with stage III gastric adenocarcinoma: a phase III multicenter, open-label, randomized controlled clinical trial protocol.
     BMC Cancer. 2021;21:56.
     PubMed     Abstract available
     
     
     
222. TONG Y, Zhao Y, Shan Z, Zhang J, et al
     CA724 predicts overall survival in locally advanced gastric cancer patients with neoadjuvant chemotherapy.
     BMC Cancer. 2021;21:4.
     PubMed     Abstract available
     
     
     
223. TAO S, Gu J, Wang Q, Zheng L, et al
     Translational control of Bcl-2 promotes apoptosis of gastric carcinoma cells.
     BMC Cancer. 2021;21:12.
     PubMed     Abstract available
     
     
     
224. WANG X, Li S, Sun Y, Li K, et al
     The protocol of a prospective, multicenter, randomized, controlled phase III study evaluating different cycles of oxaliplatin combined with S-1 (SOX) as neoadjuvant chemotherapy for patients with locally advanced gastric cancer: RESONANCE-II trial.
     BMC Cancer. 2021;21:20.
     PubMed     Abstract available
     
     
     
225. SMITH-PALMER J, Leeuwenkamp OR, Virk J, Reed N, et al
     Lutetium oxodotreotide ((177)Lu-Dotatate) for the treatment of unresectable or metastatic progressive gastroenteropancreatic neuroendocrine tumors: a cost-effectiveness analysis for Scotland.
     BMC Cancer. 2021;21:10.
     PubMed     Abstract available
     
     
     November 2020
226. EBERT K, Zwingenberger G, Barbaria E, Keller S, et al
     Correction to: Determining the effects of trastuzumab, cetuximab and afatinib by phosphoprotein, gene expression and phenotypic analysis in gastric cancer cell lines.
     BMC Cancer. 2020;20:1127.
     PubMed     Abstract available
     
     
     
227. YU P, Ye Z, Dai G, Zhang Y, et al
     Neoadjuvant systemic and hyperthermic intraperitoneal chemotherapy combined with cytoreductive surgery for gastric cancer patients with limited peritoneal metastasis: a prospective cohort study.
     BMC Cancer. 2020;20:1108.
     PubMed     Abstract available
     
     
     
228. WU R, Yang C, Ji L, Fan ZN, et al
     Prevalence of gastric cancer precursors in gastroscopy-screened adults by family history of gastric cancer and of cancers other than gastric.
     BMC Cancer. 2020;20:1110.
     PubMed     Abstract available
     
     
     
229. OKUNAKA M, Kotani D, Demachi K, Kawazoe A, et al
     Retrospective cohort study of nanoparticle albumin-bound paclitaxel plus ramucirumab versus paclitaxel plus ramucirumab as second-line treatment in patients with advanced gastric cancer.
     BMC Cancer. 2020;20:1111.
     PubMed     Abstract available
     
     
     
230. MASUI T, Ito T, Komoto I, Uemoto S, et al
     Recent epidemiology of patients with gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NEN) in Japan: a population-based study.
     BMC Cancer. 2020;20:1104.
     PubMed     Abstract available
     
     
     October 2020
231. EBERT K, Zwingenberger G, Barbaria E, Keller S, et al
     Determining the effects of trastuzumab, cetuximab and afatinib by phosphoprotein, gene expression and phenotypic analysis in gastric cancer cell lines.
     BMC Cancer. 2020;20:1039.
     PubMed     Abstract available
     
     
     
232. FUJIMORI D, Kinoshita J, Yamaguchi T, Nakamura Y, et al
     Established fibrous peritoneal metastasis in an immunocompetent mouse model similar to clinical immune microenvironment of gastric cancer.
     BMC Cancer. 2020;20:1014.
     PubMed     Abstract available
     
     
     
233. WANG JB, Xue Z, Lu J, He QL, et al
     Effect of sarcopenia on short- and long-term outcomes in patients with gastric neuroendocrine neoplasms after radical gastrectomy: results from a large, two-institution series.
     BMC Cancer. 2020;20:1002.
     PubMed     Abstract available
     
     
     
234. XUE X, Huang J, Yu K, Chen X, et al
     YB-1 transferred by gastric cancer exosomes promotes angiogenesis via enhancing the expression of angiogenic factors in vascular endothelial cells.
     BMC Cancer. 2020;20:996.
     PubMed     Abstract available
     
     
     September 2020
235. SONKAR C, Verma T, Chatterji D, Jain AK, et al
     Status of kinases in Epstein-Barr virus and Helicobacter pylori Coinfection in gastric Cancer cells.
     BMC Cancer. 2020;20:925.
     PubMed     Abstract available
     
     
     
236. LORENZEN S, Biederstadt A, Ronellenfitsch U, Reissfelder C, et al
     RACE-trial: neoadjuvant radiochemotherapy versus chemotherapy for patients with locally advanced, potentially resectable adenocarcinoma of the gastroesophageal junction - a randomized phase III joint study of the AIO, ARO and DGAV.
     BMC Cancer. 2020;20:886.
     PubMed     Abstract available
     
     
     
237. YOON JY, Brezden-Masley C, Streutker CJ
     Lgr5 and stem/progenitor gene expression in gastric/gastroesophageal junction carcinoma - significance of potentially retained stemness.
     BMC Cancer. 2020;20:860.
     PubMed     Abstract available
     
     
     August 2020
238. LEERS JM, Knepper L, van der Veen A, Schroder W, et al
     The CARDIA-trial protocol: a multinational, prospective, randomized, clinical trial comparing transthoracic esophagectomy with transhiatal extended gastrectomy in adenocarcinoma of the gastroesophageal junction (GEJ) type II.
     BMC Cancer. 2020;20:781.
     PubMed     Abstract available
     
     
     
239. CHEN J, Wang A, Ji K, Bu Z, et al
     Comparison of overall survival of gastric neoplasms containing neuroendocrine carcinoma components with gastric adenocarcinoma: a propensity score matching study.
     BMC Cancer. 2020;20:777.
     PubMed     Abstract available
     
     
     
240. JIANG H, Zheng Y, Qian J, Mao C, et al
     Safety and efficacy of sintilimab combined with oxaliplatin/capecitabine as first-line treatment in patients with locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma in a phase Ib clinical trial.
     BMC Cancer. 2020;20:760.
     PubMed     Abstract available
     
     
     
241. SHADMANI FK, Farzadfar F, Yoosefi M, Mansori K, et al
     Premature mortality of gastrointestinal cancer in Iran: trends and projections 2001-2030.
     BMC Cancer. 2020;20:752.
     PubMed     Abstract available
     
     
     July 2020
242. ZHOU K, Wang A, Ao S, Chen J, et al
     The prognosis of hepatoid adenocarcinoma of the stomach: a propensity score-based analysis.
     BMC Cancer. 2020;20:671.
     PubMed     Abstract available
     
     
     
243. LIN JL, Lin JX, Zheng CH, Li P, et al
     Relationship between aspirin use of esophageal, gastric and colorectal cancer patient survival: a meta-analysis.
     BMC Cancer. 2020;20:638.
     PubMed     Abstract available
     
     
     June 2020
244. REHKAEMPER J, Korenkov M, Quaas A, Rueschoff J, et al
     Amplification of KRAS and its heterogeneity in non-Asian gastric adenocarcinomas.
     BMC Cancer. 2020;20:587.
     PubMed     Abstract available
     
     
     
245. RICHARDS HS, Blazeby JM, Portal A, Harding R, et al
     A real-time electronic symptom monitoring system for patients after discharge following surgery: a pilot study in cancer-related surgery.
     BMC Cancer. 2020;20:543.
     PubMed     Abstract available
     
     
     
246. GU E, Song W, Liu A, Wang H, et al
     SCDb: an integrated database of stomach cancer.
     BMC Cancer. 2020;20:490.
     PubMed     Abstract available
     
     
     
247. TINTELNOT J, Goekkurt E, Binder M, Thuss-Patience P, et al
     Ipilimumab or FOLFOX with Nivolumab and Trastuzumab in previously untreated HER2-positive locally advanced or metastatic EsophagoGastric Adenocarcinoma - the randomized phase 2 INTEGA trial (AIO STO 0217).
     BMC Cancer. 2020;20:503.
     PubMed     Abstract available
     
     
     May 2020
248. O'NEILL L, Guinan E, Doyle S, Connolly D, et al
     Rehabilitation strategies following oesophagogastric and Hepatopancreaticobiliary cancer (ReStOre II): a protocol for a randomized controlled trial.
     BMC Cancer. 2020;20:415.
     PubMed     Abstract available
     
     
     April 2020
249. THERKILDSEN C, Rasmussen M, Smith-Hansen L, Kallemose T, et al
     Broadening risk profile in familial colorectal cancer type X; increased risk for five cancer types in the national Danish cohort.
     BMC Cancer. 2020;20:345.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Gastric Cancer is free of charge.